USBC (USBC) investor relations material

Executive summary

• Focused on commercializing proprietary non-invasive sensor technology for medical and industrial applications, with a primary emphasis on blood glucose monitoring and a new technology licensing initiative launched in 2025.

• Launched Generation 2 prototype for blood glucose monitoring; further clinical testing and FDA clearance required before market entry.

• Entered a Securities Purchase Agreement in June 2025 for a private placement involving 1,000 Bitcoin and $12–$15 million in cash, subject to several closing conditions.

• Announced a significant increase in authorized common stock and equity incentive plan shares in July 2025 to support future capital needs.

Financial highlights

• Net loss for the three months ended June 30, 2025 was $1.53 million, a 62.7% improvement compared to $4.10 million in the same quarter last year.

• Net loss for the nine months ended June 30, 2025 was $9.77 million, down from $12.95 million year-over-year.

• Research and development expenses for the quarter were $239,000, down 82% year-over-year; nine-month R&D expenses were $1.46 million, down 71%.

• Selling, general and administrative expenses for the quarter were $1.02 million, down 59% year-over-year; nine-month SG&A was $4.77 million, down 32%.

• Cash and cash equivalents as of June 30, 2025 were $173,000, with a net working capital deficit of $4.96 million.

Outlook and guidance

• Management anticipates continued operating losses for the foreseeable future and substantial doubt remains about the ability to continue as a going concern.

• The company expects to operate with available cash and a bridge loan until the anticipated closing of the private placement.

• Future capital needs are expected to be met through additional equity or debt financing, but there is no assurance of success.